CohBar (CWBR) – StreetInsider.com Reports
-
CohBar (CWBR) Announces Suspension of Trading, Upcoming Delisting
-
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.69%
-
CohBar (CWBR) and Morphogenesis, Inc. Enter into Definitive Merger Agreement
-
CohBar (CWBR) Halted, News Pending
-
CohBar (CWBR) granted FDA orphan drug designations for treatment of idiopathic pulmonary fibrosis (IPF)
-
CohBar (CWBR) retained Ladenburg Thalmann & Co. Inc. as a financial advisor to assist the Company in exploring strategic alternatives
-
CohBar (CWBR) granted Australian patent for obesity, diabetes, cancer, and liver disease treatement - Patent Grants
-
CohBar (CWBR) Announces 1:30 Reverse Stock Split
-
CohBar (CWBR) Announces 1-for-30 Reverse Stock Split
-
CohBar, Inc. (CWBR) Reports In-Line Q2 EPS
-
CohBar (CWBR) Appoints Effie Tozzo to its Board
-
CohBar (CWBR) granted US patent number 11,332,497 - Patent Grants
-
CohBar (CWBR) Announces Board Changes, New R&D Leadership Appointments
-
UPDATE: Cantor Fitzgerald Starts CohBar (CWBR) at Buy, $2.50 PT
-
CohBar (CWBR) Prices 20.83M Share Offering at $0.72/sh
-
CohBar (CWBR) Announces Proposed Stock and Warrant Offering, Size not Disclosed
-
CohBar (CWBR) Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
-
CohBar (CWBR) Appoints Joanne Yun to its Board
-
CohBar (CWBR) Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis
-
CohBar (CWBR) PT Raised to $4 at Maxim Group, Following Clinical Business Update
-
WBB Securities Upgrades CohBar (CWBR) to Buy
-
CohBar (CWBR) Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
-
CohBar (CWBR) Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director
-
Maxim Group Starts CohBar (CWBR) at Buy
-
CohBar (CWBR) Reports Complete Enrollment in Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
-
Aegis Capital Starts CohBar (CWBR) at Buy
-
CohBar (CWBR) Gains Mid-Day
-
CohBar (CWBR) Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS
-
Chardan Capital Markets Starts CohBar (CWBR) at Buy
-
CohBar (CWBR) Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model
-
WBB Securities Starts CohBar (CWBR) at Speculative Buy
-
Roth Capital Starts CohBar (CWBR) at Buy
-
CohBar (CWBR) Prices 12.3M Unit Offering at $1.22/Unit
-
CohBar (CWBR) Announces Proposed Public Offering of Common Stock, Warrants
-
CohBar (CWBR) Reports First Subjects Dosed in Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
-
CohBar (CWBR) to Continue CB4211 Phase 1b Clinical Trial; Study Previously Paused due to COVID-19 Pandemic
-
Brookline Capital Markets Starts CohBar (CWBR) at Buy
-
CohBar (CWBR) Announces COO Jon Stern to Step Down, Effective May 31
-
CohBar (CWBR) to Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides
-
CohBar (CWBR) Provides Update on CB4211 Phase 1b Study for NASH and Obesity
-
CohBar (CWBR) Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
-
CohBar (CWBR) Reports Complete Ph. 1a and Initiates Ph. 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity
-
CohBar (CWBR) Announces Misha Petkevich to Board
-
CohBar (CWBR) Announces Steven B. Engle as CEO
-
CohBar (CWBR) Concludes Discussions with FDA; Will Resume Phase 1a/1b Clinical Trial of CB4211
-
CohBar (CWBR) Names David Greenwood to Board
-
CohBar (CWBR) Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim CEO
-
CohBar Inc. (CWBR) Commences Clinical Study with First-in-Human Dosing of CB4211
-
CohBar (CWBR) Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at ADA
-
CohBar (CWBR) Announces the Appointment of Philippe Calais to its Board
Back to CWBR Stock Lookup
